Condition: Acute Lymphoid Leukemia · Minimal Residual Disease · Gene Abnormality · Sponsor: Instituto do Cancer do Estado de São Paulo
In this project, the investigators intend to start a prospective registry for patients with newly diagnosed Philadelphia-negative ALL from 16 years old and above in participating centers, provided that all patients will be treated with the same regimen (a pediatric regimen BFM-based incorporating peg-asparaginase). All diagnostic/follow-up (after induction and consolidation blocks) samples will be centrally biobanked at Instituto do Cancer do Estado de Sao Paulo. The main goal of this study is to examine whether the implementation of a pediatric protocol under a prospective registry can increase event-free survival (EFS) and overall survival (OS) of newly diagnosed patients in the participating centers.
This description comes directly from the study's public registry record.
Graziela Silva · 551138934677 · graziela.sasilva@hc.fm.usp.br
Bruna Moraes, MSc · 551126628112 · pesquisa.hematologia@hc.fm.usp.br
Always discuss trial participation with your own doctor first.
| Instituto do Cancer do Estado de Sao Paulo | São Paulo, São Paulo, Brazil | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05959720